ABSTRACT
Insulin resistance has emerged out as a concept linking diabetes mellitus and hypertension. Clinically it is characterized by hyperinsulinemia, hypertension, central obesity, abnormal lipid profile and cardiovascular complications. Insulin resistance is often associated with presence of anti-insulin antibodies and absent or dysfunctional insulin receptors. At molecular level insulin resistance appears to occur at the level of G-protein, kinase activation, glucose carriers (GLUT) and gene expression. Although with advent or research, the molecular mechanisms of insulin resistance are becoming more clear and there is development of new therapeutic agents like insulin sensitizers (thizolidinediones), in clinical practice, as of today, a patient with insulin resistance is looked upon as hypertensive or having diabetes mellitus. Accordingly he is taking either antihypertensives or antidiabetic drugs or both. It is thus essential to look into effects of these agents on insulin sensitivity. In recent years some scattered studies have been conducted to evaluate the effect of various antihypertensives and antidiabetics on insulin sensitivity. An antihypertensive or antidiabetic drug should directly benefit the cardiovascular risk profile of these patients. Although various newer approaches are explored to have a therapeutic benefit in insulin resistance, it is still a long way in the research, when a suitable pharmacological agent with least untoward effects will be available for the treatment of insulin residence.
Subject(s)
Enzyme Inhibitors/therapeutic use , Hyperglycemia/drug therapy , Hypoglycemic Agents/therapeutic use , Insulin Resistance , Animals , GTP-Binding Proteins/metabolism , Heart Failure/etiology , Humans , Hyperglycemia/complications , Hyperglycemia/physiopathology , Hypertension/etiology , Insulin Resistance/physiology , Monosaccharide Transport Proteins/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Phosphotransferases/metabolism , Signal Transduction/physiologyABSTRACT
Erectile dysfunction is a common and multi-factorial disease that strongly impairs the quality of life in men. During the past decade, many new therapeutic strategies have become available. But the need for oral treatment was strongly felt. This need appears to have been fulfilled with the introduction of sildenafil. The drug acts by enhancing smooth muscle relaxant effect of nitric oxide. A number of clinical studies have now proved its safety and efficacy. The drug has shaken social life all over the world and to accept this "magic pill" or not remains the question of individual choice.
Subject(s)
Erectile Dysfunction/drug therapy , Phosphodiesterase Inhibitors/pharmacology , Piperazines/pharmacology , Clinical Trials as Topic , Drug Interactions , Humans , Male , Nitric Oxide/metabolism , Phosphodiesterase Inhibitors/pharmacokinetics , Phosphodiesterase Inhibitors/therapeutic use , Piperazines/adverse effects , Piperazines/pharmacokinetics , Piperazines/therapeutic use , Purines , Sildenafil Citrate , SulfonesABSTRACT
Cataleptic effect of pentazocine in mice was affected by pretreatment with dexfenfluramine, fluoxetine, buspirone, p-chlorophenylalanine, cyproheptadine, mianserin, cisapride, ondansetron, pindolol and propranolol. The results suggest that drugs which influence the activity of central serotonergic systems do modulate pentazocine-induced catalepsy in mice.
